Advertisement
Screener

MANNKIND CORP (MNKD) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

MANNKIND CORP Operating Expenses

MANNKIND CORP (MNKD) reported Operating Expenses of $29.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-05

  • MANNKIND CORP operating expenses for the quarter ending 2026-06-30 was $29.54M, a 43.62% increase year-over-year.
  • MANNKIND CORP operating expenses for the quarter ending 2025-06-30 was $20.57M, a 0.94% increase year-over-year.
  • MANNKIND CORP operating expenses for the quarter ending 2024-12-31 was $19.60M, a 8.51% increase year-over-year.
  • MANNKIND CORP operating expenses for the quarter ending 2024-09-30 was $18.02M, a 26.44% increase year-over-year.
  • MANNKIND CORP operating expenses for fiscal 2025 was $87.96M, a 14.83% increase from fiscal 2024.
  • MANNKIND CORP operating expenses for fiscal 2024 was $76.60M, a 22.03% increase from fiscal 2023.
  • MANNKIND CORP operating expenses for fiscal 2023 was $62.77M, a 9.17% increase from fiscal 2022.
  • MANNKIND CORP operating expenses for fiscal 2022 was $57.50M, a 47.97% increase from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 6 monthOperating Expenses 9 monthOperating Expenses 12 monthOperating Expenses 244 monthOperating Expenses 247 monthOperating Expenses 250 monthOperating Expenses 253 monthOperating Expenses 256 monthOperating Expenses 259 monthOperating Expenses 263 monthOperating Expenses 265 monthOperating Expenses 268 monthOperating Expenses 271 monthOperating Expenses 275 monthOperating Expenses 277 monthOperating Expenses 280 monthOperating Expenses 283 month
2026-06-30$29.54M
10-Q · filed 2026-08-05
$47.01M
10-Q · filed 2026-08-05
2025-12-31$87.96M
10-K · filed 2026-02-26
2025-06-30$20.57M
10-Q · filed 2026-08-05
$38.08M
10-Q · filed 2026-08-05
2024-12-31$19.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$37.63M
derived: sum of 2 quarters · filed 2026-02-26
$58.00M
derived: sum of 3 quarters · filed 2026-02-26
$76.60M
10-K · filed 2026-02-26
2024-09-30$18.02M
10-Q · filed 2024-11-07
$38.40M
derived: sum of 2 quarters · filed 2024-11-07
$57.00M
10-Q · filed 2024-11-07
$75.06M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$20.38M
10-Q · filed 2024-08-07
$38.98M
10-Q · filed 2024-08-07
$57.04M
derived: sum of 3 quarters · filed 2026-02-26
$71.30M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$18.60M
10-Q · filed 2024-05-08
$36.66M
derived: sum of 2 quarters · filed 2026-02-26
$50.92M
derived: sum of 3 quarters · filed 2026-02-26
$65.16M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$18.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$32.32M
derived: sum of 2 quarters · filed 2026-02-26
$46.56M
derived: sum of 3 quarters · filed 2026-02-26
$62.77M
10-K · filed 2026-02-26
2023-09-30$14.25M
10-Q · filed 2024-11-07
$28.49M
derived: sum of 2 quarters · filed 2024-11-07
$44.70M
10-Q · filed 2024-11-07
$60.83M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$14.24M
10-Q · filed 2024-08-07
$30.45M
10-Q · filed 2024-08-07
$46.57M
derived: sum of 3 quarters · filed 2025-02-26
$64.03M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$16.21M
10-Q · filed 2024-05-08
$32.34M
derived: sum of 2 quarters · filed 2025-02-26
$49.80M
derived: sum of 3 quarters · filed 2025-02-26
$62.71M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$16.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$33.58M
derived: sum of 2 quarters · filed 2025-02-26
$46.50M
derived: sum of 3 quarters · filed 2025-02-26
$57.50M
10-K · filed 2025-02-26
2022-09-30$17.46M
10-Q · filed 2023-11-07
$30.38M
derived: sum of 2 quarters · filed 2023-11-07
$41.37M
10-Q · filed 2023-11-07
$52.81M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30$12.91M
10-Q · filed 2023-08-07
$23.91M
10-Q · filed 2023-08-07
$35.35M
derived: sum of 3 quarters · filed 2024-02-27
$45.23M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31$11.00M
10-Q · filed 2023-05-09
$22.43M
derived: sum of 2 quarters · filed 2024-02-27
$32.32M
derived: sum of 3 quarters · filed 2024-02-27
$42.24M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31$11.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
$21.32M
derived: sum of 2 quarters · filed 2024-02-27
$31.25M
derived: sum of 3 quarters · filed 2024-02-27
$38.86M
10-K · filed 2024-02-27
2021-09-30$9.89M
10-Q · filed 2022-11-08
$19.81M
derived: sum of 2 quarters · filed 2022-11-08
$27.42M
10-Q · filed 2022-11-08
2021-06-30$9.93M
10-Q · filed 2022-08-09
$17.54M
10-Q · filed 2022-08-09
2020-12-31$24.64M
10-K · filed 2023-02-23
2016-03-31$20.01M
10-Q · filed 2016-05-09
$292.88M
derived: sum of 2 quarters · filed 2016-05-09
$318.88M
derived: sum of 3 quarters · filed 2016-05-09
$342.93M
derived: sum of 4 quarters · filed 2016-05-09
2015-12-31$272.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$298.87M
derived: sum of 2 quarters · filed 2016-03-15
$322.92M
derived: sum of 3 quarters · filed 2016-03-15
$344.65M
10-K · filed 2016-03-15
2015-09-30$26.00M
10-Q · filed 2015-11-09
$50.05M
derived: sum of 2 quarters · filed 2015-11-09
$71.79M
10-Q · filed 2015-11-09
$101.89M
derived: sum of 4 quarters · filed 2016-05-09
2015-06-30$24.05M
10-Q · filed 2015-08-10
$45.79M
10-Q · filed 2015-08-10
$75.89M
derived: sum of 3 quarters · filed 2016-05-09
$114.16M
derived: sum of 4 quarters · filed 2016-05-09
2015-03-31$21.74M
10-Q · filed 2016-05-09
$51.84M
derived: sum of 2 quarters · filed 2016-05-09
$90.11M
derived: sum of 3 quarters · filed 2016-05-09
$159.95M
derived: sum of 4 quarters · filed 2016-05-09
2014-12-31$30.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$68.37M
derived: sum of 2 quarters · filed 2016-03-15
$138.22M
derived: sum of 3 quarters · filed 2016-03-15
$179.63M
10-K · filed 2016-03-15
2014-09-30$38.27M
10-Q · filed 2015-11-09
$108.11M
derived: sum of 2 quarters · filed 2015-11-09
$149.52M
10-Q · filed 2015-11-09
$196.14M
derived: sum of 4 quarters · filed 2016-03-15
$2.38B
10-Q · filed 2014-11-10
2014-06-30$69.85M
10-Q · filed 2015-08-10
$111.26M
10-Q · filed 2015-08-10
$157.87M
derived: sum of 3 quarters · filed 2016-03-15
$202.64M
derived: sum of 4 quarters · filed 2016-03-15
$2.35B
10-Q · filed 2014-08-11
2014-03-31$41.41M
10-Q · filed 2015-05-11
$88.03M
derived: sum of 2 quarters · filed 2016-03-15
$132.79M
derived: sum of 3 quarters · filed 2016-03-15
$174.38M
derived: sum of 4 quarters · filed 2016-03-15
$2.28B
10-Q · filed 2014-05-12
2013-12-31$46.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$91.38M
derived: sum of 2 quarters · filed 2016-03-15
$132.96M
derived: sum of 3 quarters · filed 2016-03-15
$169.40M
10-K · filed 2016-03-15
$2.23B
10-K · filed 2014-03-03
2013-09-30$44.76M
10-Q · filed 2014-11-10
$86.35M
derived: sum of 2 quarters · filed 2014-11-10
$122.78M
10-Q · filed 2014-11-10
$156.27M
derived: sum of 4 quarters · filed 2015-03-02
$2.19B
10-Q · filed 2013-11-12
2013-06-30$41.59M
10-Q · filed 2014-08-11
$78.02M
10-Q · filed 2014-08-11
$111.51M
derived: sum of 3 quarters · filed 2015-03-02
$147.03M
derived: sum of 4 quarters · filed 2015-03-02
$2.14B
10-Q · filed 2013-08-09
2013-03-31$36.44M
10-Q · filed 2014-05-12
$69.92M
derived: sum of 2 quarters · filed 2015-03-02
$105.44M
derived: sum of 3 quarters · filed 2015-03-02
$149.50M
derived: sum of 4 quarters · filed 2015-03-02
$2.10B
10-Q · filed 2013-05-10
2012-12-31$33.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$69.01M
derived: sum of 2 quarters · filed 2015-03-02
$113.06M
derived: sum of 3 quarters · filed 2015-03-02
$147.00M
10-K · filed 2015-03-02
$2.06B
10-K · filed 2013-03-18
2012-09-30$35.52M
10-Q · filed 2013-11-12
$79.58M
derived: sum of 2 quarters · filed 2013-11-12
$113.51M
10-Q · filed 2013-11-12
$144.09M
derived: sum of 4 quarters · filed 2014-03-03
$2.03B
10-Q · filed 2012-11-09
2012-06-30$44.05M
10-Q · filed 2013-08-09
$77.99M
10-Q · filed 2013-08-09
$108.57M
derived: sum of 3 quarters · filed 2014-03-03
$141.34M
derived: sum of 4 quarters · filed 2014-03-03
$2.00B
10-Q · filed 2012-08-09
2012-03-31$33.93M
10-Q · filed 2013-05-10
$64.51M
derived: sum of 2 quarters · filed 2014-03-03
$97.28M
derived: sum of 3 quarters · filed 2014-03-03
$136.47M
derived: sum of 4 quarters · filed 2014-03-03
$1.95B
10-Q · filed 2012-05-10
2011-12-31$30.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$63.35M
derived: sum of 2 quarters · filed 2014-03-03
$102.54M
derived: sum of 3 quarters · filed 2014-03-03
$140.59M
10-K · filed 2014-03-03
$1.92B
10-K · filed 2012-03-15
2011-09-30$32.77M
10-Q · filed 2012-11-09
$71.96M
derived: sum of 2 quarters · filed 2012-11-09
$110.01M
10-Q · filed 2012-11-09
$142.10M
derived: sum of 4 quarters · filed 2013-03-18
$1.89B
10-Q · filed 2011-11-04
2011-06-30$39.19M
10-Q · filed 2012-08-09
$77.24M
10-Q · filed 2012-08-09
$109.33M
derived: sum of 3 quarters · filed 2013-03-18
$151.87M
derived: sum of 4 quarters · filed 2013-03-18
$1.85B
10-Q · filed 2011-08-04
2011-03-31$38.05M
10-Q · filed 2012-05-10
$70.14M
derived: sum of 2 quarters · filed 2013-03-18
$112.68M
derived: sum of 3 quarters · filed 2013-03-18
$150.04M
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$32.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$74.63M
derived: sum of 2 quarters · filed 2013-03-18
$111.99M
derived: sum of 3 quarters · filed 2013-03-18
$152.59M
10-K · filed 2013-03-18
2010-09-30$42.54M
10-Q · filed 2011-11-04
$79.90M
derived: sum of 2 quarters · filed 2011-11-04
$120.50M
10-Q · filed 2011-11-04
2010-06-30$37.36M
10-Q · filed 2011-08-04
$77.96M
10-Q · filed 2011-08-04
2009-12-31$209.78M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19